Showing results (81-90 of 223) with videos related to
Sort By:
Pageof 23
Bioorganic & Medicinal Chemistry|May 16, 2007
Modulating paclitaxel bioavailability for targeting prostate cancerSrinivas K Kumar, Simon A Williams, John T Isaacs, et al.Journal of Immunology (Baltimore, Md. : 1950)|February 13, 2013
Proteolysis of complement factors iC3b and C5 by the serine protease prostate-specific antigen in prostatic fluid and seminal plasmaMichael L Manning, Simon A Williams, Christine A Jelinek, et al.The Prostate|June 9, 2016
Mutational Analysis of Prostate-Specific Antigen Defines the Intrinsic Proteolytic Activity of the proPSA ZymogenNiquiche Sangster-Guity, Becky Tu-Sekine, Daniel M Raben, et al.Cancer Research|July 4, 1998
Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigenS R Denmeade, A Nagy, J Gao, et al.The Journal of Foot and Ankle Surgery : Official Publication of the American College of Foot and Ankle Surgeons|April 8, 2024
Diabetic Osteomyelitis: Oral versus Intravenous Antibiotics at a Single Level 1 Academic Medical Trauma CenterJennifer A Kipp, Lindsay K LeSavage, Joni K Evans, et al.Cancer Research|February 28, 2002
Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblastsJacek Pinski, Ashani Weeraratna, Aarti R Uzgare, et al.Clinical Psychology & Psychotherapy|March 27, 2025
Clinician Diagnostic Ratings and Countertransference Reactions Towards Grandiose and Vulnerable NarcissismNicholas J S Day, Marko Biberdzic, Ava Green, et al.Personality and Mental Health|September 5, 2025
Coercive Control and Intimate Partner Violence: Relationship With Personality Disorder Severity and Pathological NarcissismNicholas J S Day, David Kealy, Marko Biberdzic, et al.The Journal of Urology|November 13, 2012
Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasiaMostafa M Elhilali, Peter Pommerville, Richard C Yocum, et al.Bioorganic & Medicinal Chemistry|August 28, 1999
Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cellsS B Christensen, A Andersen, H Kromann, et al.Pageof 23